Top 5 Drug Type | Count |
---|---|
Synthetic peptide | 1 |
mRNA vaccine | 1 |
Target |
Mechanism MUC1 inhibitors [+2] |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date31 Oct 2024 |
Sponsor / Collaborator |
Start Date30 Sep 2024 |
Sponsor / Collaborator |
Start Date19 Jul 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
FhHDM-1 | Multiple Sclerosis More | Preclinical |
UTIs mRNA vaccine(Starpharma) | Urinary Tract Infections More | Preclinical |
Anti-MUC1 CAR-T cell/PD-1 knockout engineered T cell therapy (Guangzhou Anjie Biomedical Technology) ( MUC1 ) | Non-Small Cell Lung Cancer More | Pending |
Ant-21 ( miR-21 ) | Pulmonary Disease, Chronic Obstructive More | Pending |